Method | Evaluation | MCC | Q2 | Se | Sp | PPV | NPV | AUC |
---|---|---|---|---|---|---|---|---|
SEQ-NEIGHB | cross-validation ∗ | 0.41 | 77.65 | 55.09 | 85.57 | 57.35 | 84.45 | 0.78 |
unseen-mutation | 0.36 | 75.80 | 51.16 | 84.48 | 53.74 | 83.08 | 0.78 | |
unseen-residue | 0.14 | 71.65 | 21.28 | 89.42 | 41.52 | 76.30 | 0.67 | |
unseen-protein | 0.14 | 69.09 | 29.45 | 83.13 | 38.21 | 76.89 | 0.67 | |
SEQ-FREQ | cross-validation ∗ | 0.33 | 72.63 | 57.37 | 77.98 | 48.00 | 83.92 | 0.75 |
unseen-mutation | 0.29 | 69.27 | 58.64 | 73.02 | 43.36 | 83.36 | 0.74 | |
unseen-residue | 0.22 | 69.30 | 43.40 | 78.44 | 41.54 | 79.70 | 0.68 | |
unseen-protein | 0.18 | 65.71 | 47.70 | 72.09 | 37.71 | 79.55 | 0.66 | |
EASE | cross-validation ∗ | 0.45 | 78.54 | 60.95 | 84.72 | 58.33 | 86.08 | 0.81 |
unseen-mutation | 0.41 | 77.05 | 57.91 | 83.80 | 55.74 | 84.96 | 0.81 | |
unseen-residue | 0.26 | 73.26 | 37.63 | 85.84 | 48.40 | 79.59 | 0.72 | |
unseen-protein | 0.23 | 71.27 | 39.76 | 82.44 | 44.50 | 79.44 | 0.70 | |
EASE-AA | cross-validation ∗ | 0.43 | 76.69 | 63.35 | 81.37 | 54.43 | 86.35 | 0.80 |
unseen-mutation | 0.38 | 74.71 | 60.64 | 79.66 | 51.23 | 85.17 | 0.79 | |
unseen-residue | 0.34 | 73.23 | 56.11 | 79.27 | 48.86 | 83.65 | 0.76 | |
unseen-protein | 0.35 | 73.24 | 58.79 | 78.36 | 49.04 | 84.30 | 0.77 |